Emotion Endophenotypes in Schizophrenia (SCHIZOIMAGEN)

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Unknown

Conditions: Schizophrenia

Treatments: Genetic: quantitative measures of mRNA; Other: MRI (Magnetic resonance imaging); Genetic: Polymorphism (SNP in DNA); Other: Neuropsychological assessment

Study type: Interventional

Funder types: Other

Identifiers

NCT02834208

2015-38

2015-A01475-44 (Other Identifier)

Details and patient eligibility

About

Schizophrenia is an invalidating psychiatric illness with a strong genetic component characterized by abnormal processing of emotional information. This alteration in emotion processing has been described in acute as well as in remission phases of the illness. It has also been found in healthy relatives of patients with schizophrenia and in subjects at high risk of psychosis. Thus, alterations in emotional information processing are not only linked to the prognosis but can also be considered as a marker of vulnerability of schizophrenia. In addition, schizophrenia patients differ from healthy controls in neural activity in brain regions implicated in emotions processing. However, interpretation of findings in patients is limited by confounding factors, such as antipsychotic treatments or alterations due to the course of illness. Also, there is no data concerning genetic factors (polymorphisms or gene expression) underlying these patterns of cerebral activation in emotion information processing.

So, the main objective of this study is to compare the cerebral activity of schizophrenia patients to that of healthy siblings and healthy controls in an emotional processing task.

Enrollment: 105 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female participant, right-handed, aged from 18 to 45 years old
• Haven given their written consent
• DSM-5 (Diagnostic and Statistical Manual of Mental Disorders version 5) diagnosis of schizophrenia
• Remitted phase (criteria of Andreasen)
• Stable doses of antipsychotics during the last 6 weeks
• No severe somatic illness
• Normal clinical exam
• Inscription to the social security

Exclusion criteria

• Women in genitally active period without contraception
• Women pregnant or breast feeding
• Participants presenting a severe somatic /neurologic condition
• Present/history in the last year of alcohol or drug abuse
• Participating in another clinical study or still in period of exclusion of a previous clinical trial
• Contraindication to an MRI test (metallic foreign body, pacemaker, heart valve, chirurgical clip, claustrophobia...)

Trial design

105 participants in 3 patient groups

Schizophrenia subjects

Experimental group

Description:

35 patients suffering from schizophrenia

Treatment:

Genetic: Polymorphism (SNP in DNA)

Other: MRI (Magnetic resonance imaging)

Other: Neuropsychological assessment

Genetic: quantitative measures of mRNA

Healthy siblings

Other group

Description:

35 healthy siblings of the patients suffering from schizophrenia

Treatment:

Genetic: Polymorphism (SNP in DNA)

Other: MRI (Magnetic resonance imaging)

Other: Neuropsychological assessment

Genetic: quantitative measures of mRNA

Healthy controls

Other group

Description:

35 healthy "controls "patients

Treatment:

Genetic: Polymorphism (SNP in DNA)

Other: MRI (Magnetic resonance imaging)

Other: Neuropsychological assessment

Genetic: quantitative measures of mRNA